Sustained Hair Regrowth With Ritlecitinib to Week 48 in Patients With Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
March 2023
in “
SKIN The Journal of Cutaneous Medicine
”
New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide → Studysummary This study observed that most patients with alopecia areata experienced sustained scalp hair regrowth after 48 weeks of ritlecitinib treatment, with safety consistent with prior findings. Our plain-language summary of this paper — not a Tressless recommendation.
In the ALLEGRO phase 2b/3 study, a post hoc analysis revealed that the majority of patients with alopecia areata (AA) experienced sustained scalp hair regrowth through Week 48 after receiving ritlecitinib treatment, particularly those with a Severity of Alopecia Tool (SALT) score of ≤20 or ≤10 after Week 24. The safety profile of ritlecitinib up to Week 48 for SALT ≤20 responders was consistent with the overall study population. Serious adverse events included chemical poisoning and suicidal behavior in one patient in the 200/30 mg group and pulmonary embolism in one patient in the 50 mg group.
